Japanese pharma company Santen (TYO: 4536) has appointed Shigeo Taniuchi as head of Santen Europe.
He will manage the company’s European business strategies and operations from April 1. Mr Taniuchi has spent 15 years working at Santen in top-level management and global business leadership, and has served as senior vice president of commercialization for Santen Europe since September 2014. He previously held positions including general manager of corporate planning and corporate development division.
Mr Taniuchi said: "I am very pleased to lead the development of Santen’s business in Europe in order for the company to become one of the major companies of reference in ophthalmology in Europe. I am looking forward to working closely with customers and Santen’s European team, in order to reinforce our presence and become a key player in the European ophthalmic sector. Santen is on the right track for continued growth and expansion with innovative products and services to improve patient vision and quality of life.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze